WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wuxi Biologics (Cayman) ( (HK:2269) ) just unveiled an announcement.
WuXi Biologics (Cayman) Inc., a Hong Kong-listed biologics contract development and manufacturing organization, serves global pharmaceutical and biotechnology companies with end-to-end services. The company plays a key role in enabling partners to advance biologic therapies from early development through large-scale production.
The company will host conference calls on March 25, 2026, to present its 2025 annual results and update investors on its business operations. By publishing the full presentation alongside the announcement and offering calls in both Chinese and English, WuXi Biologics aims to ensure equal and timely access to information for shareholders and potential investors, while cautioning them about the inherent uncertainty of forward-looking information.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. is a Hong Kong-listed biopharmaceutical services company focused on biologics development and manufacturing. It provides contract research, development, and manufacturing services to global pharmaceutical and biotech clients, supporting their biologic drug pipelines and commercial supply needs.
Average Trading Volume: 34,772,480
Technical Sentiment Signal: Hold
Current Market Cap: HK$134.1B
For an in-depth examination of 2269 stock, go to TipRanks’ Overview page.
